Article Figures & Tables
Figures
- Figure 1:
Use of valsartan and non-valsartan angiotensin receptor blockers (ARBs) from 2015 to 2019.
- Figure 2:
Use of angiotensin receptor blockers (ARBs), angiotensin-converting-enzyme (ACE) inhibitors and other antihypertensives (calcium channel blockers, β-blockers, diuretics) from 2015 to 2019.
Tables
- Table 1:
Use of antihypertensive drugs before and after the valsartan recall on July 9, 2018
No. of drugs dispensed (% change)* All ARBs Valsartan Non-valsartan ARBs ACE inhibitors Other hypertensives† Total June 2018 1 577 509 362 231 1 215 278 1 939 144 4 673 711 8 190 364 September 2018‡ 1 545 591 (−2.0) 152 892 (−57.8) 1 392 699 (14.6) 1 835 269 (−5.4) 4 568 105 (−2.3) 7 948 965 (−2.9) December 2019§ 1 753 924 (13.5) 173 224 (13.3) 1 580 700 (13.5) 1 976 285 (7.7) 5 365 868 (17.5) 9 096 077 (14.4) Note: ACE = angiotensin converting enzyme, ARB = angiotensin receptor blockers.
↵* Monthly number of prescriptions dispensed.
↵† Other antihypertensives include calcium channel blockers, β-blockers, diuretics.
↵‡ Percent change from June 2018 to September 2018.
↵§ Percent change from September 2018 to December 2019.
In this issue
Article tools
Respond to this article
Related Articles
Cited By...
- No citing articles found.